FDA rejects Actavis norethindrone contraceptive patch
This article was originally published in Scrip
Executive Summary
There were no good wishes to Actavis this week from the FDA, which doled out a Christmas Eve complete response letter (CRL) to the company on its progestin-only contraceptive patch, known as the Norethindrone Transdermal Delivery System.